BioCentury | Dec 11, 2019
Clinical News

Leo’s IL-13 mAb hits in atopic dermatitis; how it stacks up against Dupixent remains a question mark

...Over a year after the primary completion of tralokinumab’s Phase III studies, Leo Pharma has said...
...dupilumab from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi (Euronext:SAN; NASDAQ:SNY). According to Leo Pharma A/S, tralokinumab...
BioCentury | Mar 30, 2018
Emerging Company Profile

Skin-to-skin

...developing tralokinumab (CAT-354), a human IgG4 mAb against IL-13. Leo has exclusive, worldwide rights to tralokinumab...
BioCentury | Nov 3, 2017
Clinical News

AZ's asthma candidate misses again in Phase III

...AstraZeneca plc (LSE:AZN; NYSE:AZN) said tralokinumab (CAT-354) missed the primary endpoint in both the Phase III...
...tralokinumab failed to significantly reduce oral corticosteroid use vs. placebo. In May, the pharma said tralokinumab...
...therapy (see BioCentury, July 11, 2016 ). AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Tralokinumab (CAT-354...
BioCentury | Nov 1, 2017
Clinical News

AZ's asthma candidate misses again in Phase III

...AstraZeneca plc (LSE:AZN; NYSE:AZN) said tralokinumab (CAT-354) missed the primary endpoint in both the Phase III...
...be reached for next steps for the program. On the primary endpoint of STRATOS 2, tralokinumab...
...tralokinumab failed to significantly reduce oral corticosteroid use vs. placebo. In May, the pharma said tralokinumab...
BioCentury | Oct 6, 2017
Finance

Coasting on catalysts

...Irritable bowel syndrome with constipation (IBS-C) Ph III T3MPO-2 data 4Q17 AstraZeneca plc (LSE:AZN; NYSE:AZN) Tralokinumab...
BioCentury | Jul 28, 2017
Clinical News

Leo starts Phase III trial of tralokinumab for atopic dermatitis

...Leo Pharma A/S (Ballerup, Denmark) began a Phase III trial of tralokinumab (CAT-354) to treat atopic...
...Quality Index (DLQI) and Scoring Atopic Dermatitis (SCORAD) scores. Leo has exclusive, worldwide rights to tralokinumab...
...IL-13. Leo Pharma A/S , Ballerup, Denmark AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Tralokinumab (CAT-354...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

...AstraZeneca plc (LSE:AZN; NYSE:AZN) Lynparza olaparib Ovarian cancer PDUFA date 3Q17 AstraZeneca plc (LSE:AZN; NYSE:AZN) Tralokinumab...
BioCentury | May 12, 2017
Clinical News

AZ's tralokinumab misses in Phase III asthma trial

...AstraZeneca plc (LSE:AZN; NYSE:AZN) said 300 mg tralokinumab (CAT-354) every 2 weeks missed the primary endpoint...
...in the Phase III STRATOS 1 trial in about 2,247 patients with severe uncontrolled asthma. Tralokinumab...
...see BioCentury, July 11, 2016 ). AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Tralokinumab ( CAT-354...
BioCentury | May 10, 2017
Clinical News

AZ's asthma candidate misses in Phase III

...AstraZeneca plc (LSE:AZN; NYSE:AZN) said tralokinumab (CAT-354) missed the primary endpoint in the Phase III STRATOS...
...population. In a subpopulation of patients with an elevated biomarker associated with increased IL-13 activity, tralokinumab...
...be the focus of its analysis for the ongoing Phase III STRATOS 2 trial of tralokinumab...
BioCentury | Mar 31, 2017
Clinical News

Tralokinumab: Ph IIb data

...adult patients with moderate to severe atopic dermatitis showed that subcutaneous 150 and 300 mg tralokinumab...
...p=0.011). The 45 mg dose of tralokinumab missed the EASI endpoint. Low-, mid- and high-dose tralokinumab...
...Leo Pharma A/S , Ballerup, Denmark AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Tralokinumab ( CAT-354...
Items per page:
1 - 10 of 36